Mary Wheeler

For two decades I have been a deal-maker leading pharma licensing and M&A deals I see a flow of compelling biotech cos that are not (yet) a fit for traditional venture funding.

Investment returns -- Years leading M&A acquisitions with public pharma companies and leading licensing collaborations that are a major source of non-dilutive funding for startup biotech enables me to advise my portfolio companies on how to maximize exits. I also specialize in advising and leading companies that opt to raise little to no venture before exiting-instead they make money from buyers (like Big Pharma where i used to work).

Impact investments-- Certain biotech companies are incredibly compelling because of the patient population or breakthrough innovation. But some of these may require longer time to returns and/or substantial future rounds to reach exit or may pose a 'black box' risk until certain milestones are hit- I label these opportunities IMPACT for my angel backers.